LakeShore Biopharma rebrands for global market expansion

On May 24, 2024, YS Biopharma Co., Ltd. (Nasdaq: YS) made a significant announcement regarding a change in its operations. The renowned biopharmaceutical company, previously known as YS Biopharma, has decided to rebrand itself as LakeShore Biopharma Co., Ltd. This strategic move aims to strengthen the company's position in the global market and improve its brand recognition.

The name change from YS Biopharma to LakeShore Biopharma will not have any impact on the rights of shareholders or the financial stability of the company. LakeShore Biopharma's ordinary shares and warrants will continue to be traded on the Nasdaq exchange, with the ticker symbols changing to 'LSB' and 'LSBPW' respectively, starting from May 28, 2024.

Specializing in the development of vaccines and therapeutic biologics for infectious diseases and cancer, LakeShore Biopharma utilizes its proprietary PIKA® immunomodulating technology platform to create preventive and treatment solutions for various viral infections such as Rabies, Coronavirus, Hepatitis B, and Influenza.

With operations in China, the United States, Singapore, and the Philippines, LakeShore Biopharma is guided by a management team with extensive experience in the biopharmaceutical sector. The company's dedication to innovation and global expansion underscores its commitment to advancing healthcare solutions on a worldwide scale.

For more information about LakeShore Biopharma, please visit investor.ysbiopharma.com.

The rebranding of YS Biopharma to LakeShore Biopharma signifies a strategic shift towards enhancing global market presence and brand image. With a focus on developing innovative healthcare solutions for infectious diseases and cancer, LakeShore Biopharma is poised to make a significant impact in the biopharmaceutical industry.